Company Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases.
Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.
The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration.
The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011.
Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
| Country | United States |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Joel Lewis |
Contact Details
Address: 4960 Peachtree Industrial Boulevard, Suite 240 Norcross, Georgia 30071 United States | |
| Phone | (678) 620-3186 |
| Website | galectintherapeutics.com |
Stock Details
| Ticker Symbol | GALT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001133416 |
| CUSIP Number | 363225202 |
| ISIN Number | US3632252025 |
| Employer ID | 04-3562325 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jack W. Callicutt CPA | Chief Financial Officer, Treasurer and Corporate Secretary |
| Jeff Katstra | Head of CMC and Pharmaceutical Development |
| Khurram Jamil M.D. | Chief Medical Officer |
| Beth Knowles | Executive Assistant and Officer Manager |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2024 | 8-K | Current Report |
| Dec 3, 2024 | ARS | Filing |
| Dec 3, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Dec 3, 2024 | DEF 14A | Other definitive proxy statements |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Oct 4, 2024 | 144 | Filing |
| Sep 9, 2024 | 8-K | Current Report |
| Aug 13, 2024 | 8-K | Current Report |